May 12, 2021

Aminet Market Reports

Market and Industry Analytics

Neuroendocrine Tumors Market Shows Unbelievable Growth With Detailed Analysis. Major Players are Ipsen Pharma, Regeneron Pharmaceuticals, Mylan N.V, Teva Pharmaceutical Industries Ltd

A comprehensive data and information provided in the report can be utilized by Healthcare  industry to be acquainted with the present and upcoming opportunities and clarify the future investment in the market. Neuroendocrine Tumors market document is a meticulous analysis of existing scenario of the market, which covers several market dynamics. The market study of this report takes into consideration a market attractiveness analysis, where each segment is benchmarked based on its market size, growth rate, and general attractiveness. In global Neuroendocrine Tumors market report; a systematic investment analysis has been performed which forecasts impending opportunities for the market players.

Request for sample copy or PDF Here @

Global neuroendocrine tumors market is rise gradually to an estimated value of USD 2.80 Billion by 2026 registering a CAGR of 10.2% in the forecast period of 2019-2026. Increasing prevalence of neuroendocrine tumors and accelerating demand of clinical treatment and novel therapies indicates the significant growth of market.

Few of the major competitors currently working in the global neuroendocrine tumors market are, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Amgen, Inc.,  Ipsen Pharma, GlaxoSmithKline Plc, Regeneron Pharmaceuticals, Mylan N.V, Sanofi S.A, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., Advanced Accelerator Applications and among others

Market Definition: Global Neuroendocrine Tumors Market

Neuroendocrine tumors are an oncology disorder in which cancer arises from neuroendocrine cells and proliferate almost all over the body. The organs affected by neuroendocrine tumors are mainly, gastrointestinal (GI) tract, gallbladder, pancreas, lungs and thyroid. It is seen rarely in thymus, kidneys, liver, prostate, skin and ovaries. The patient may experience indigestion, abdominal pain, difficulty in breathing, muscle weakness, jaundice, weight loss etc.

According to the statistics published in American Society of Clinical Oncology, the total prevalent population of neuroendocrine tumors in United States was over 170,000, it is estimated that 12,000 new cases of patients in United States diagnosed with neuroendocrine tumors each year.

Browse Detailed TOC Here @

Segmentation: Global Neuroendocrine Tumors Market

Neuroendocrine Tumors Market : By Site of Origin

  • Carcinoid tumors in the lungs
  • Pancreatic neuroendocrine tumors
  • Medullary thyroid carcinoma
  • Merkel cell carcinoma
  • Pheochromocytoma of the adrenal gland
  • Small cell lung cancer
  • Large cell lung cancer
  • Others

Neuroendocrine Tumors Market : By Therapy Type

  • Chemotherapy
  • Hormonal therapy
  • Immunotherapy
  • Surgery
  • Medication
  • Others

Neuroendocrine Tumors Market : By Mechanism of Cation type

  • Somatostatin analogs
  • Tyrosine kinase inhibitor
  • Peptide receptor radionuclide
  • Alfa-interferon
  • Proton-pump inhibitors
  • Others

Neuroendocrine Tumors Market : By Drug Type

  • Everolimus
  • Sunitinib malate
  • Lorlatinib
  • Nivolumab
  • Dacomitinib
  • Brigatinib
  • Durvalumab
  • Atezolizumab
  • Alectinib
  • Crizotinib
  • Topotecan hydrochloride
  • Bevacizumab
  • Others

Neuroendocrine Tumors Market : By Route of administration

  • Oral
  • Intravenous
  • Others

Neuroendocrine Tumors Market : By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Neuroendocrine Tumors Market : By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Key Developments in the Market:

  • In January 2018, Advanced Accelerator Applications received FDA approval for Lutathera (lutetium Lu 177 dotatate), a radioactive somatostatin receptor acting as a Peptide Receptor Radionuclide Therapy (PRRT), indicated for the treatment of adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previously, drug also received Orphan Drug designation by both the US FDA and European Medicines Agency (EMA)
  • In April 2019, Merck & Co., Inc received expanded approval from the US FDA for Keytruda (pembrolizumab), an anti-PD-1 therapy as a first line treatment of patients with stage III non-small cell lung cancer

Neuroendocrine Tumors Market Drivers

  • Increase in prevalence rate of neuroendocrine tumor in geriatric population worldwide
  • Accelerating demand of treatment and novel therapies
  • Rising awareness about treatment and technological advancement is driving the growth of market

Neuroendocrine Tumors Market Restraints

  • Effective treatment is either unavailable or unaffordable
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
  • Lack of awareness about novel therapies and clinical development for neuroendocrine tumors

Competitive Analysis: Global Neuroendocrine Tumors Market

Global neuroendocrine tumors market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of neuroendocrine tumors market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa

Neuroendocrine Tumors Market : Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global neuroendocrine tumors market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Key Questions Answered in Global Neuroendocrine Tumors Market Report

  • What is the scope of growth of companies in the global Neuroendocrine Tumors market?
  • What will be the Y-o-Y growth of the global Neuroendocrine Tumors market between 2020 and 2027?
  • What is the influence of changing trends in technologies on the global Neuroendocrine Tumors market?
  • Will North America continue to be the most profitable market for Neuroendocrine Tumors providers?
  • Which factors will hamper the growth of the global Neuroendocrine Tumors market during the forecast period?
  • Which are the leading companies in the global Neuroendocrine Tumors market?

Want Full Report? Enquire Here @

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail: [email protected]